Varicella-zoster virus (VZV) causes both varicella and herpes zoster. Varicella, or chickenpox, is a prevalent childhood disease. It is highly contagious and life-threatening, with symptoms presented as red, itchy, blister-like rashes. VZV can be dangerous in pregnant women, adolescents, babies, and individuals with weakened immunity. Varicella can be prevented by vaccination1. Herpes zoster originates when dormant VZV in infected individuals reactivates, and usually occurs later in life.
According to the World Health Organisation (WHO) in 2014, at least 4.2 million serious complications required hospitalization, and 4200 related fatalities were reported annually. Severity of varicella is typically higher in adults, with at least 4-50 times increased hospitalization risk for adults aged ≥ 45 years old, and a 174-fold fatality rate in children between the ages of 5 and 142.
Varicella Vaccine, Live
Our vaccine is a lyophilized preparation of the live attenuated Oka strain of varicella zoster virus with a positive conversion rate of 98.89%. Each dose of the reconstituted vaccine contains not less than 103.3 pfu of the attenuated virus. The vaccine needs to be reconstituted with the diluent that comes in the pre-filled syringe. Our vaccine exports to countries such as Côte d’Ivoire, South Korea, India and many more.
A total of 75 million doses have been used worldwide. The varicella vaccine is indicated for individuals 12 months and older.
The COVID-19 pandemic has underscored the importance of research and development in preparation for future pandemics. In Sino-Innovax, we focus on predicting new infectious landscapes and challenge the frontiers of vaccine science. We are open to collaboration with innovative and cutting-edge technologies and products which align with our strategic interest.
Plasma being the largest component in the human blood, helps individuals to stay healthy. Plasma-derived products are prepared from the separation of proteins in the human plasma and are vital in the treatment of autoimmune diseases. a. Human Immunoglobulin (pH4) for Intravenous Injection IVIG targets a wide range of autoimmune diseases […]
Our parent company China National Biotec Group (CNBG) is the 6th largest vaccine manufacturer in the world. CNBG has the capacity of manufacturing approximately 700 million doses of 50 various human vaccines (a year?) Sino-Innovax is also committed to benefit people from all around the globe through our constant development of efficient and novel vaccines. […]